Tag: papillary-only disease
-
ImmunityBio’s Anktiva Wins FDA Expansion in Bladder Cancer
The FDA expanded ImmunityBio’s Anktiva plus BCG to high-grade papillary-only bladder cancer. The decision extends existing CIS efficacy evidence to a related patient population, broadening the IL-15 receptor agonist’s approved role.